Luis Barreto

ORCID: 0000-0001-6264-5494
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bacterial Infections and Vaccines
  • Pneumonia and Respiratory Infections
  • SARS-CoV-2 and COVID-19 Research
  • Influenza Virus Research Studies
  • Virus-based gene therapy research
  • Viral Infections and Immunology Research
  • Respiratory viral infections research
  • Viral gastroenteritis research and epidemiology
  • Power Line Communications and Noise
  • ICT Impact and Policies
  • Electrodeposition and Electroless Coatings
  • Advanced Machining and Optimization Techniques
  • Electronic Health Records Systems
  • Immunodeficiency and Autoimmune Disorders
  • Peripheral Neuropathies and Disorders
  • Celiac Disease Research and Management
  • Access Control and Trust
  • Environmental and Industrial Safety
  • Plant and soil sciences
  • Military Technology and Strategies
  • Aerospace Engineering and Energy Systems
  • Soil Science and Environmental Management
  • Academic Research in Diverse Fields
  • Virology and Viral Diseases
  • Error Correcting Code Techniques

CanSino (China)
2021-2022

National Academies of Sciences, Engineering, and Medicine
2013

Polytechnic Institute of Viana do Castelo
2011

Sanofi (Canada)
2006

Background. Pertussis is increasingly recognized as an important cause of cough illness in adolescents and adults. Purpose. To evaluate the safety antibody response to a single dose adult formulation five component (pertussis toxoid, filamentous hemagglutinin, pertactin, fimbriae 2 3) acellular pertussis vaccine (aP) combined with diphtheria tetanus toxoids (TdaP) inactivated poliovirus (TdaP-IPV) adults assess second subset Population setting. The study addressed 1207 healthy participants...

10.1097/00006454-200004000-00003 article EN The Pediatric Infectious Disease Journal 2000-04-01

During outbreaks of measles, measles vaccine is recommended for infants considered to be at risk who are 6 months age and older. In a prospective trial the serologic response early immunization has been evaluated in 125 given monovalent 8.5 measles-mumps-rubella 15 months. The vaccination was measured by plaque reduction neutralization (PRN) assay enzyme immunoassay. Infants were grouped mother's history: natural immunity (n = 60, Group 1); killed followed live, further attenuated 22, 2);...

10.1097/00006454-199501000-00003 article EN The Pediatric Infectious Disease Journal 1995-01-01

The optimal composition and antigen content of acellular pertussis vaccines is not known. Two with differrent quantities toxoid (10 20 μg) filamentous hemagglutinin (5 identical 69 kD protein (3 fimbriae 2 3 combined diphtheria tetanus toxoids were compared in a randomized, double-blind study 2,050 infants undergoing their primary immunization series at 8 centers the US Canada. A 6:1 increased to lower allocation was used; 96% received doses completed study. ‘clinically significant’ local...

10.3109/00365549509019022 article EN Scandinavian Journal of Infectious Diseases 1995-01-01

Novel adjuvants hold the promise for developing effective modern subunit vaccines capable of appropriately modulating immune response against challenging diseases such as those caused by chronic and/or intracellular pathogens and cancer. Over past decade there has been intensive research into discovering new adjuvants, however, their translation routine clinical use is lagging. To stimulate discussion identify opportunities networking collaboration among various stakeholders, a Canadian...

10.4161/hv.26972 article EN Human Vaccines & Immunotherapeutics 2013-11-05

10.26678/abcm.cobem2023.cob2023-0637 article EN Proceedings of the 26th International Congress of Mechanical Engineering 2023-01-01

ABSTRACT Background To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5 × 10 viral particles per 0.5 mL dose), we conducted single-dose, randomised, double-blind, placebo-controlled, parallel group (3:1 Ad5-nCoV:placebo), phase 3 trial (Prometheus). Methods From 11-September-2020 to 05-May-2021, across six sites in Russian Federation, 496 participants were injected with either placebo or...

10.1101/2022.03.01.22271507 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2022-03-11
Coming Soon ...